Palvella Therapeutics Inc Logo
US6979471090
A40RA6
PVLA

Palvella Therapeutics Inc

Prognoza

Średnia cena docelowa analityków wynosi 210,03 € (+59,11%). Mediana wynosi 211,67 € (+60,36%).

Kupuj
  12
Trzymaj
  0
Sprzedaj
  0

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • Palvella presents QTORIN NDA and focuses on rare skin and vascular diseases

    At the Cantor Health conference Palvella outlined its focused strategy for rare skin diseases and vascular anomalies and confirmed submission of an NDA to the FDA for QTORIN (rapamycin) to treat microcystic lymphatic malformations (microLM). If granted a Priority Review, approval could occur in the first half of 2027; Phase III data showed improvement in 95% of patients. The company estimates at least 30,000 diagnosed US microLM patients and aims for an annual treatment price range of $100,000–$200,000, relies on extensive patent protection through at least 2038, and is pursuing additional programs for cutaneous venous malformations and DSAP. » Więcej na de.investing.com


  • Palvella prepares NDA submission for QTORIN Rapamycin and builds sales organization

    Palvella plans to file a rolling NDA for QTORIN Rapamycin for microcystic lymphatic malformations later this year and targets a potential US approval in the first half of 2027. The Phase III trial met its primary endpoint: 95% of patients showed improvement and 86% were rated as markedly/very markedly improved. The company has USD 251 million in cash, is preparing a commercial launch with a 40-person sales team and is targeting a treatment price of USD 100,000–200,000 per patient/year. In parallel, Palvella plans to expand QTORIN into additional indications (cutaneous venous malformations, angiokeratomas, DSAP) and to broaden the pipeline by year-end. » Więcej na de.investing.com


  • Palvella advances launch preparations; stock rises despite Q2 loss

    Palvella reported a second-quarter loss of $1.52 per share (expectation -$1.16) and no revenue, but the stock rose 4.2% pre-market. The company has about $251 million in cash following a $230 million financing round and raised its expected 2026 cash burn to $85–95 million to expand sales, patient services and launch activities. Lead program QTORIN Rapamycin remains on track for an NDA submission in the second half of 2026 and potential FDA approval in the first half of 2027; Phase III data showed a 95% improvement in the primary endpoint. Management emphasizes financial flexibility and a focus on approval and commercialization preparations, but notes risks from regulation, execution and higher costs. » Więcej na de.investing.com


  • Palvella Therapeutics moves to Nasdaq Global Market after strong share price rise

    Palvella Therapeutics has received approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Market; the move takes effect at the start of trading on Wednesday and the ticker symbol PVLA remains unchanged. The stock rose 444% last year and is currently at $125.79, with a market capitalization of about $1.8 billion. Analyst views are mixed: InvestingPro considers the stock overvalued, while Stephens rates Palvella “Overweight” with a $220 price target. The company reported strong financial and operational progress in Q1 2026, a robust cash position and promising clinical results, although stock reactions reflected expectations about future earnings and market conditions. » Więcej na de.investing.com


  • Palvella reports $261.9m liquidity and aims for QTORIN market launch in 2027

    Palvella reported strong phase‑3 results for QTORIN (rapamycin) in microcystic lymphatic malformations and plans an NDA filing in H2 2026 targeting a U.S. launch in H1 2027. The company closed Q1 with $261.9m in liquidity after an upsized $230m capital raise and views the funds as sufficient through approval. Palvella cites a U.S. sales potential of over $1bn for the main indication and is advancing multiple pipeline programs (cutaneous venous malformations, angiokeratomas, DSAP) with upcoming phase‑2/3 milestones. Despite the progress, the stock fell about 12% as investors weighed the timing to profitability and the valuation. » Więcej na de.investing.com

Dane finansowe

W ostatnim kwartale Palvella Therapeutics Inc osiągnęła przychody w wysokości 0 € i zysk netto w wysokości -21,76 mln €

(EUR) wrzesień 2026
YoY
Przychody 0 -
Zysk brutto 0 -
Zysk netto -21,76 mln 125,05%
EBITDA -19,27 mln 6712,85%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
1,91 mld €
Liczba akcji
14,62 mln
Maksimum/minimum z 52 tygodni
164,18 € - 65,89 €
Dywidendy Nie
Beta
-0,17
C/Z (PE Ratio)
-26,06
PEG (PEG Ratio)
7,33
C/WK (PB Ratio)
10,52
C/S (PS Ratio)
0,00

Profil spółki

Nazwa
Palvella Therapeutics Inc
CEO
Wesley H. Kaupinen
Siedziba Wayne, pa
Stany Zjednoczone
Strona internetowa
Sektor
Ochrona zdrowia
Branża
Biotechnologia
Pracownicy 29

Symbole giełdowe

Giełda Symbol
NASDAQ
PVLA
🍪

Parqet  używa plików cookie. Dowiedz się więcej